People | October 13, 2025
Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Medico Remedies receives order worth US$ 1,781,000
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Subscribe To Our Newsletter & Stay Updated
